Big Pharma Split (TSX:PRM) Asset Turnover: 0.19 (As of Dec. 2025)


TSX:PRM Big Pharma Split Corp TSX:PRM
7 GF Score
Price C$11.61
GF Value C$1.80
View Full Analysis

What is Big Pharma Split Asset Turnover?

Big Pharma Split TSX:PRM 7 Asset Turnover is 0.19 as of Dec. 2025. GuruFocus rates TSX:PRM with a GF Score™ of 7/100 and a GF Value™ of C$1.80.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Big Pharma Split's Revenue for the six months ended in Dec. 2025 was C$5.48 Mil. Big Pharma Split's Total Assets for the quarter that ended in Dec. 2025 was C$28.80 Mil. Therefore, Big Pharma Split's Asset Turnover for the quarter that ended in Dec. 2025 was 0.19.

Asset Turnover is linked to ROE % through Du Pont Formula. Big Pharma Split's annualized ROE % for the quarter that ended in Dec. 2025 was 66.40%. It is also linked to ROA % through Du Pont Formula. Big Pharma Split's annualized ROA % for the quarter that ended in Dec. 2025 was 36.20%.


Big Pharma Split  (TSX:PRM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Big Pharma Split's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=10.428/15.706
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(10.428 / 10.966)*(10.966 / 28.803)*(28.803/ 15.706)
=Net Margin %*Asset Turnover*Equity Multiplier
=95.09 %*0.3807*1.8339
=ROA %*Equity Multiplier
=36.20 %*1.8339
=66.40 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Big Pharma Split's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=10.428/28.803
=(Net Income / Revenue)*(Revenue / Total Assets)
=(10.428 / 10.966)*(10.966 / 28.803)
=Net Margin %*Asset Turnover
=95.09 %*0.3807
=36.20 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Big Pharma Split Asset Turnover Related Terms


Big Pharma Split Asset Turnover Historical Data

* Premium members only.

The historical data trend for Big Pharma Split's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Big Pharma Split Asset Turnover Chart

Big Pharma Split Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only 0.18 0.10 0.01 0.02 0.19

Big Pharma Split Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.07 -0.05 0.00 0.19

TSX:PRM vs BLK, BX, KKR: Asset Turnover Comparison

For the Asset Management subindustry, Big Pharma Split's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Big Pharma Split Asset Turnover vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Big Pharma Split's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Big Pharma Split's Asset Turnover falls into.


TSX:PRM
7GF Score
Big Pharma Split Corp TSX:PRM
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Big Pharma Split Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Big Pharma Split's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=5.555/( (26.302+31.841)/ 2 )
=5.555/29.0715
=0.19

Big Pharma Split's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=5.483/( (25.765+31.841)/ 2 )
=5.483/28.803
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.19 mean?
Big Pharma Split (TSX:PRM) has a Asset Turnover of 0.19 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Big Pharma Split and its competitors.
Is Big Pharma Split's Asset Turnover too high?
Big Pharma Split's current Asset Turnover is 0.19. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's Asset Turnover compare to BLK and BX?
Big Pharma Split's Asset Turnover of 0.19 can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for an Asset Management company?
A good Asset Turnover depends on the Asset Management industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Big Pharma Split and its competitors. Big Pharma Split's current Asset Turnover is 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current Asset Turnover of 0.19. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current Asset Turnover is 0.19. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current Asset Turnover is 0.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Big Pharma Split (TSX:PRM) Overvalued in 2026?

Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued. The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.

Key valuation signals for TSX:PRM:

  • Asset Turnover: 0.19
  • GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
  • GF Score™: 7/100

No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Big Pharma Split Business Description

Other Exchanges PRM.PR.A.PFD:Canada
Address 610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score

Get the complete analysis for TSX:PRM

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$11.61
Price
C$1.80
GF Value